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AbsTrACT
Introduction To inform the WHO Guideline on self-care 
interventions, we conducted a systematic review of the 
impact of ovulation predictor kits (OPKs) on time-to-
pregnancy, pregnancy, live birth, stress/anxiety, social 
harms/adverse events and values/preferences.
Methods Included studies had to compare women 
desiring pregnancy who managed their fertility with and 
without OPKs, measure an outcome of interest and be 
published in a peer-reviewed journal. We searched for 
studies on PubMed, CINAHL, LILACS and EMBASE through 
November 2018. We assessed risk of bias assessed using 
the Cochrane tool for randomised controlled trials (RCTs) 
and the Evidence Project tool for observational studies, and 
conducted meta-analysis using random effects models to 
generate pooled estimates of relative risk (RR).
results Four studies (three RCTs and one observational 
study) including 1487 participants, all in high-income 
countries, were included. Quality of evidence was low. 
Two RCTs found no difference in time-to-pregnancy. All 
studies reported pregnancy rate, with mixed results: one 
RCT from the 1990s among couples with unexplained 
or male-factor infertility found no difference in clinical 
pregnancy rate (RR: 1.09, 95% CI 0.51 to 2.32); two more 
recent RCTs found higher self-reported pregnancy rates 
among OPK users (pooled RR: 1.40, 95% CI 1.08 to 1.80). A 
small observational study found higher rates of pregnancy 
with lab testing versus OPKs among women using donor 
insemination services. One RCT found no increase in 
stress/anxiety after two menstrual cycles using OPKs, 
besides a decline in positive affect. No studies measured 
live birth or social harms/adverse events. Six studies 
presented end-users’ values/preferences, with almost 
all women reporting feeling satisfied, comfortable and 
confident using OPKs.
Conclusion A small evidence base, from high-income 
countries and with high risk of bias, suggests that home-
based use of OPKs may improve fertility management 
when attempting to become pregnant with no meaningful 
increase in stress/anxiety and with high user acceptability.
systematic review registration number PROSPERO 
registration number CRD42019119402.
InTroduCTIon
Global estimates show that approximately 
15%–25% of couples are unable to become 
pregnant despite attempting for 5 years or 
more.1 2 Infertility is typically diagnosed if a 
woman is unable to become pregnant after 12 
months of regular condom-less intercourse,3 
although this timeframe may vary by age (eg, 
advanced maternity), anatomical abnormali-
ties (eg, tubal occlusion, fibroids, physical disa-
bilities) or disease (eg, HIV, endometriosis, 
Key questions
What is already known?
 ► Better timing of condom-less intercourse can 
improve the probability of achieving pregnancy; 
ovulation predictor kits (OPKs) are accurate and 
commercially available.
What are the new findings?
 ► Three randomised controlled trials (RCTs) show evi-
dence that OPKs may increase pregnancy rates.
 ► One RCT found slight or no increase in stress/anxiety 
from using OPKs.
 ► Ovulation predictor kids are generally acceptable to 
women and improve fertility awareness.
What do the new findings imply?
 ► Home ovulation testing appears to be an acceptable 
intervention that can increase pregnancy rates, im-
prove reproductive health knowledge and encour-
age shared decision-making for couples who are 
attempting to achieve pregnancy.  on A
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oncofertility).4 Clinically, 20%–30% of infertility cases 
are attributable to the male partner,5 a similar percentage 
to the female partner and up to 50% to both partners.6 
Couples diagnosed as infertile, or women who require 
assistance to become pregnant, may turn to medically 
assisted reproduction using various diagnostics and inter-
ventions, including ovulation induction, ovarian stimula-
tion and ovulation triggering, as well as procedures using 
processed semen of a partner or donor such as intrau-
terine, intracervical and intravaginal insemination or egg 
collection with external in vitro fertilisation.7 However, 
many such options are unaffordable or inaccessible to 
women or couples in resource-constrained settings.
Better timing of condom-less intercourse or, if required 
or desired, the self-intravaginal insemination of semen, 
during the woman’s fertile window can be supported 
using ovulation predictor kits (OPKs). OPKs are readily 
available in many settings worldwide without prescrip-
tion, including at pharmacies, drugstores, convenience 
stores and supermarkets, as well as online websites which 
ship globally. These kits do not predict ovulation, per se, 
but rather the surge of luteinising hormone (LH) that 
precedes ovulation while also tracking corresponding 
oestrogen levels.8 OPKs do not directly pinpoint a peak 
fertility day and may need multiple pregnancy attempts 
within the appropriate timeframe during a woman’s 
menstrual cycle. OPKs are fairly accurate at predicting 
ovulation and the fertile window.9 10 They increase fertility 
awareness about when ovulation should occur during the 
woman’s cycle and may alert her to potential menstrual 
cycle abnormalities. Women with HIV sero-discordant 
partners could use OPKs to time intercourse and limit 
exposure to condom-less sex in order to reduce the risk of 
transmission of sexually transmitted infections, including 
HIV.11 12 Single women, women who wish to observe 
specific religious or cultural traditions, migrant/irreg-
ular workers or couples in unconsummated marriages 
(for instance, due to male erectile dysfunction or phys-
ical disabilities) may wish to use OPKs to appropriately 
time condom-less intercourse or attempt self-intravaginal 
insemination.13
Home-based use of OPKs has the potential to increase 
autonomy and agency for women globally. Increasing 
reproductive health awareness by using OPKs could yield 
greater knowledge concerning ovulation and a woman’s 
fertile window. Use of OPKs through a human rights-
based approach could be particularly empowering for 
women and girls who face barriers to enacting decisions in 
relation to their sexuality, reproduction, health and well-
being. A 2015 Cochrane review by Manders et al exam-
ined randomised controlled trial (RCT) evidence for the 
effectiveness of timed intercourse using both OPKs and 
other fertility awareness methods on the outcomes of live 
birth, pregnancy and adverse events, including stress.8 
They found that that timed intercourse using OPKs may 
increase pregnancy rates compared with intercourse 
without ovulation prediction, with no difference in stress. 
In order to develop normative guidance by the WHO on 
self-care interventions for sexual and reproductive health 
and rights, we conducted a systematic review of available 
evidence of effectiveness and values and preferences 
surrounding the use of home-based, self-initiated ovula-
tion prediction kits for fertility management to attempt 
pregnancy.
MeTHods
We conducted this systematic review in accordance to 
Preferred Reporting Items for Systematic review and 
Meta-Analyses (PRISMA) guidelines.14
research question and inclusion criteria
Should home-based OPKs be made available as an addi-
tional approach for fertility management?
Population: Women attempting to become pregnant.
Intervention: Fertility management that includes home-
based OPKs.
Comparison: Fertility management that does not include 
home-based OPKs (clinician-led assessment of ovulation 
only or no ovulation prediction).
Outcomes: (1) Time-to-pregnancy; (2) Pregnancy; (3) 
Live birth; (4) Stress/anxiety; (5) Social harms/adverse 
events (eg, device-related issues, coercion, violence [eg, 
intimate-partner violence, violence from family members 
or community members ], psychosocial harm, self-harm, 
suicide, stigma, discrimination).
To be included in the effectiveness (PICO) review, an 
article had to (1) have a comparative study design exam-
ining women who managed their fertility using home-
based OPKs to women who did not manage their fertility 
using home-based OPKs (ie, clinician-led assessment only 
or no ovulation prediction), (2) evaluate one or more 
of the outcomes listed above and (3) be published in a 
peer-reviewed journal.
Inclusion was not restricted by location of the interven-
tion. No language or publication date restrictions were 
used in the search.
OPKs could include both urine-based and serum-based 
kits and any modality (stick, monitor, digital, electronic 
slip that connects to a phone and so on). In order to 
focus on OPKs as a specific biomedical and biochemical 
intervention, the other behavioural and non-biochem-
ical methods of ovulation prediction, such as calendar/
standard day/fertility awareness methods, basal body 
temperature monitoring, Billings/cervical mucus moni-
toring methods, use of fertility beads and so on, were not 
included.15–17
search strategy and screening process
We searched the electronic databases PubMed, CINAHL, 
LILACS and EMBASE through 21 November 2018, using 
search terms for ovulation and prediction. The full 
search strategy is available in online supplementary file 
1. Secondary reference searching was also conducted 
on all included articles and on studies included in the 
Manders et al Cochrane review.8 We searched for ongoing 
RCTs were searched through  clinicaltrials. gov, the WHO 
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International Clinical Trials Registry Platform, the Pan 
African Clinical Trials Registry and the Australian New 
Zealand Clinical Trials Registry.
After title/abstract screening, full-text articles were 
obtained of all potential studies. Two reviewers inde-
pendently assessed all full-text articles for study inclusion 
eligibility and resolved differences through consensus.
data extraction and analysis
Two reviewers independently extracted data and 
conducted the risk of bias assessments. Standardised data 
extraction forms included fields for study citation, objec-
tives, location, population characteristics, description 
of the OPK, description of any additional intervention 
components, study design, sample size, follow-up periods 
and loss to follow-up, analytic approach, reported numer-
ical outcomes, results and limitations.
For RCTs, risk of bias was assessed using the Cochrane 
Collaboration’s tool for assessing risk of bias.18 For obser-
vational studies that presented comparative data, study 
rigour was assessed using the Evidence Project risk of bias 
tool for intervention evaluations.19
Data were analysed according to coding categories and 
outcomes, following the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
approach used by WHO for guideline development.20 
If studies included other methods in conjunction with 
OPKs (ie, a multifactorial intervention), we planned 
to compare the intervention group to a control group 
receiving the same other methods but excluding OPK. 
Where multiple studies reported the same outcome, we 
conducted meta-analysis using random effects models to 
generate pooled risk ratios (RR) using the programme 
Comprehensive Meta-Analysis.18 Where studies reported 
both intention-to-treat and per-protocol analyses, we 
used intention-to-treat data. Where comparative event 
data were reported at multiple timepoints, we used data 
from the final timepoint. Heterogeneity was assessed 
using I-squared statistics, and funnel plots were created 
to examine the potential for publication bias if there 
were a sufficient number of included studies. Data from 
RCTs and non-randomised studies were meta-analysed 
separately.
Values and preferences review
The same search was used to identify studies presenting 
information on end-users’ values and preferences for 
home ovulation testing with OPKs. Studies were included 
if they presented primary data examining individuals’ 
values and preferences regarding OPKs. These studies 
could be qualitative or quantitative in nature, but had 
to present primary data collection; opinion pieces and 
review articles were excluded. Values and preferences 
literature also underwent data extraction by two reviewers 
using standardised forms to collect information on study 
location, study population, study design and key findings. 
Results were summarised qualitatively.
Patient and public involvement
A patient representative from the USA contributed to 
the systematic review protocol and is a coauthor on this 
review. Patients were also involved in a global survey of 
values and preferences and in focus group discussions 
with vulnerable communities conducted to inform the 
WHO Guideline on self-care interventions, and thus 
play a significant role in the overall recommendation 
informed by this review.
resulTs
Electronic database searching retrieved 1026 results, and 
an additional four were identified through searching trial 
registries, contacting experts in the field and secondary 
searching (figure 1). After removing duplicates, there 
were 766 unique citations. After initial screening of titles 
and abstracts, 101 citations remained. After two inde-
pendent reviewers screened in duplicate and gained 
consensus, 14 articles were pulled for full-text review. Of 
these, four were included in the effectiveness (PICO) 
review21–24 and seven in the values and preferences 
review.21 23–28
study characteristics
Table 1 presents summary characteristics of the four 
included studies presenting evidence on benefits and 
harms. The four studies included 1487 total women 
(or couples); individual study sample sizes ranged from 
117 to 1000. Articles were published between 1992 and 
2013 for studies taking place between 1991 and 2010. 
All studies were conducted in high-income countries. 
Two studies (one each in the UK and the USA) recruited 
general population women nationwide, and two studies 
(one each in Scotland and Australia) recruited women 
undergoing fertility treatment or investigation. Partici-
pants' ages ranged from 18 to 43.
All studies included a study arm where women used 
a commercially available home ovulation prediction 
kit: one study allowed intervention group participants 
to choose one of three available home-based OPKs 
(Conceive, Clearplan or Predictor),21 and the rest used 
a single product (Clearblue Digital Home Ovulation 
Test, also known as Clearblue Easy Fertility Monitor 
or Clearplan).22–24 Three studies had a control group 
where participants were given general information about 
fertility and ways to spontaneously improve achieving 
pregnancy: one gave instructions via telephone about 
the best time during the menstrual cycle to achieve preg-
nancy;22 another allowed control group members to use 
other aids to attempt pregnancy including home ovula-
tion tests other than the intervention;23 the third asked 
participants not to use any additional methods to deter-
mine ovulation timing.24 One study had its control group 
send urine samples for lab LH testing to time donor 
insemination.21
All studies measured the outcome pregnancy (indi-
cated by self-report via home-based pregnancy test, 
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Figure 1 PRISMA flow diagram of the different phases of a systematic review. OPK, ovulation predictor kit; PRISMA, 
Preferred Reporting Items for Systematic review and Meta-Analyses.
except for one study which confirmed pregnancy via 
ultrasound22), but follow-up periods ranged from two to 
six menstrual cycles. Because of incomplete data for the 
third cycle, one study only analysed data from the first 
two cycles.23 Two studies measured time-to-pregnancy, 
and one study reported on stress/anxiety. No studies 
presented comparative data on the outcomes of live birth 
or social harms/adverse events.
Three RCTs and one prospective cohort study were 
included. Risk of bias among RCTs was generally high. 
Blinding was impossible, given the intervention. All 
participants knew whether they were in the intervention 
or control group, increasing risk of performance bias. 
The self-reported pregnancy outcome may have suffered 
from detection bias, as lack of blinding could lead to 
greater awareness of fertility, and increased frequency 
of pregnancy testing, and thus greater rates of positive 
pregnancy tests. Couples using OPKs may also have had 
increased frequency of intercourse, which may have 
impacted the likelihood of pregnancy and time-to-preg-
nancy. There is high risk of publication bias, given the 
small number and small sample size of included studies. 
In addition, two studies were funded by the OPK manu-
facturer,23 24 and one study had its intervention delivered 
by the manufacturer;21 because of the commercial nature 
of OPKs, there may be some concern that data yielding 
negative results have not been published. The single 
observational study was of moderate quality. Table 2 
presents an assessment of risk of bias for each study. The 
GRADE table for this review with quality assessment by 
outcome is available in online supplementary file 2.
For each of the main outcomes, results are presented 
below and in table 1.
Time to pregnancy
Two RCTs measured time-to-pregnancy, indicated by 
positive pregnancy tests.23 24 There was no evidence of a 
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Table 3 Summary of pregnancy outcomes
Pregnancy outcome # effect sizes RR 95% CI P value (RR) Q statistic P value (Q) I-squared
Pregnancy (clinical and self-reported) 3 RCTs 1.36 1.07 to 1.73 0.01 0.43 0.81 0.00
Pregnancy (clinical only) 1 RCT 1.09 0.51 to 2.32 0.85 – – –
Pregnancy (self-reported only) 2 RCTs 1.40 1.08 to 1.80 0.01 0.06 0.81 0.00
Pregnancy (clinical only) 1 observational 0.35 0.15 to 0.86 0.01 – – –
OPK, ovulation predictor kit; RCT, randomised controlled trial; RR, risk ratio comparing using OPKs to not using OPKs for fertility 
management.
Figure 2 Meta-analysis of likelihood of pregnancy (clinical and self-reported) from RCTs comparing OPKs to no OPKs. OPKs, 
ovulation predictor kits; RCTs, randomised controlled trials.
statistically significant difference in time-to-pregnancy in 
either study.
In one study among the general population, 46 of 500 
participants in the OPK group (9.2%) became pregnant 
during the first menstrual cycle, compared with 27 of 500 
(5.4%) in the control group; during the second cycle, 
another 23 in the OPK group became pregnant (cumu-
latively 22.8%) and another 23 in the control group 
(cumulatively 10%).23
The other study, whose general population participants 
had been assessed within a fertility clinic for their likely 
ability to become pregnant through condom-less inter-
course and were presumed fertile, found pregnancies 
among women at the beginning of the first menstrual 
cycle (22 of 87 in the OPK group [25.2%] compared with 
13 of 68 in the control group [19.1%]); after the first 
cycle, 30 of 55 women using OPKs were found pregnant 
(54.5%) compared with 9 of 54 (16.6%) in the control 
group and after the second cycle, 7 of 44 women using 
OPKs were found pregnant (15.9%) compared with 6 of 
43 (14.0%) in the control group.24 Pre-cycle 1 pregnan-
cies were included in this study, as participants were sent 
study materials after recruitment and randomisation and 
may have become pregnant by the first timepoint (day 6 
of cycle 1).
Pregnancy
All included studies reported pregnancy rates, whether 
clinical or self-reported pregnancy (table 3).
Meta-analysis of three RCTs found that using a home-
based OPK for timing intercourse was associated with 
higher pregnancy rates than not using OPKs (pooled 
RR: 1.36, 95% CI 1.07 to 1.73) (figure 2).22–24 One RCT 
published in 1992 among couples with unexplained 
or male-factor infertility measuring clinical pregnancy 
(confirmed by ultrasound) found no difference in preg-
nancy rate (RR: 1.09, 95% CI 0.51 to 2.32).22 Meta-anal-
ysis of two more recent RCTs (one conducted 2001–2002 
and the other in 2010) among the general population 
measuring pregnancy via home-based pregnancy tests 
found higher pregnancy rates when using OPKs (pooled 
RR: 1.40, 95% CI 1.08 to 1.80) (figure 3).23 24
One prospective cohort study published in 1996 treated 
174 cycles in 64 home-testing participants and 110 cycles 
in 53 lab-testing participants with donor insemination.21 
The clinical pregnancy rate in home-tested cycles was 
significantly reduced when using OPKs compared with 
lab-testing (RR: 0.35, 95% CI 0.15 to 0.86).
stress/anxiety
One RCT reported levels of stress/anxiety stratified by 
OPK use.24 The study measured stress in five different 
ways, using scales to self-report stress, positive/negative 
affect and general health, as well as two biochemical 
measures (urinary cortisol and estrone-3-glucuronide 
(E3G)). Across all measurement approaches, there was 
no evidence of difference in stress, besides a statisti-
cally significant decrease in positive affect score, at the 
final study timepoint (beginning of menstrual cycle 3) 
between the group using an OPK and the control group 
(table 4).
Values and preferences
Six studies in seven articles reported end-users' values 
and preferences regarding OPKs, three of which 
related to studies reported above for the PICO review 
(table 5).21 23–28
Three articles reported results from women from the 
general population attempting to become pregnant who 
had participated in an RCT. In the USA, women who 
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Figure 3 Meta-analysis of likelihood of pregnancy (self-reported only) from RCTs comparing OPKs to no OPKs. OPKs, 
ovulation predictor kits; RCTs, randomised controlled trials.
Table 4 Summary of stress outcomes
Stress outcome 
(from one RCT)







n p valueMean SD n Mean SD n
PSS 17.76 6.48 37 15.78 6.25 40 1.98 −0.91 to 4.87 1 RCT 77 0.18
PANAS: positive 
affect
29.75 10.24 36 34.26 8.06 38 −4.51 −8.77 to −0.25 1 RCT 74 0.04
PANAS: negative 
affect
17.55 6.97 38 16.90 6.64 40 0.65 −2.42 to 3.72 1 RCT 78 0.67
SF-12: physical 
attributes
41.86 4.00 38 41.12 3.14 40 0.74 −0.88 to 2.36 1 RCT 78 0.37
SF-12: mental 
attributes
46.40 7.15 38 46.15 5.11 40 0.25 −2.54 to 3.04 1 RCT 78 0.86
Cortisol:creatinine 
ratio
139.30 59.03 37 156.23 89.44 38 −16.90 −51.87 to 18.07 1 RCT 75 0.34
E3G:creatinine 
ratio
101.59 52.34 37 95.24 52.43 38 6.35 −17.76 to 30.46 1 RCT 75 0.60
SF-12: Short-Form-12 Health Survey. It is a short, reliable, validated generic questionnaire for functional health status and outcomes, with 
both physical and mental health composite scores. Higher scores indicate higher health-related quality of life (range 0–100).
E3G:creatinine ratio: ratio of estrone-3-glucuronide (ng/mL) to creatinine (g/dL). E3G is an oestrogen marker associated with depression and 
anxiety, where a higher ratio indicates higher depression/anxiety.
PANAS: The Positive and Negative Affect Schedule (PANAS) comprises 10 positive affects (interested, excited, strong, enthusiastic, proud, 
alert, inspired, determined, attentive, active) and 10 negative affects (distressed, upset, guilty, scared, hostile, irritable, ashamed, nervous, 
jittery, afraid), where higher scores indicate stronger emotion (range 10–50).
Higher scores indicate higher stress, based on perceptions of how unpredictable, uncontrollable and overloaded participants find their lives 
(range 0–40).
OPK, ovulation predictor kit; PSS, perceived stress scale; RCT, randomised controlled trial; n, sample size.
used the OPK were sent a consumer satisfaction question-
naire.23 OPK users found the device to be easy or very 
easy to use (90%) and convenient or very convenient 
(80%). Most believed the OPK was accurate or very accu-
rate (73%) and were confident or very confident that it 
identified their fertile days (71%).
In the UK, another RCT reported qualitative findings 
from follow-up semistructured telephone interviews, 
reported in two articles.24 28 All participants from both 
OPK and control groups found OPKs appealing. Women 
who had used OPKs found the digital ovulation tests easy 
to use and understand, especially compared with visual 
read tests. Half of the OPK group felt that they better 
understood changes in their bodies after using the OPK 
and self-reported not feeling any pressure or stress from 
the test. Almost all OPK users said the OPK met their 
expectations and would consider purchasing and using 
this product in future.
Interviewees also discussed perceived pros and cons 
of home ovulation testing.24 28 The most frequently 
mentioned advantages of OPKs were understanding their 
menstrual cycle and pinpointing ovulation time, which 
participants felt increased their likelihood of getting preg-
nant. They liked their increased knowledge and decreased 
stress, as well as the OPK's digital charting/tracking 
and precision, saying that this ability to plan pregnancy 
attempts with their partner made them feel proactive and 
more relaxed. Women felt the OPKs provided emotional 
support, giving reassurance and providing a helping 
hand (both to become pregnant and to alert the couple 
when something went wrong). Some believed OPKs 
also improved relationships with their partner, building 
teamwork and decreasing stress. Some participants also 
noticed that OPKs helped them identify anovular cycles, 
prompting them to seek medical assistance earlier—a 
useful benefit of negative or abnormal results.
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Table 5 Description of included studies for the values and preferences review





Couples using donor insemination services who had used 
OPKs (not lab-based urinary LH testing) to time insemination
Prospective cohort study 
(acceptability questionnaire 
mailed after completing 
study)









Women attempting to become pregnant
Women were 18–39 years old, low-income, racial/ethnic 
minorities, medically underserved and living in urban areas. 
Most had at least one previously unplanned pregnancy.
Cross-sectional survey
Sample size: 22 women
Ovulation test 







Female patients at infertility clinics
Women were 26–40 years old (mean age 33). Median family 
income was $47 000. Women had participated in a previous 
study of endometriosis and infertility. Couples had been 
attempting to become pregnant for an average of 3.2 years 
(range 2–15 years).
Cross-sectional study (mail 
survey)
Sample size: 26 women




USA (national) Women attempting to become pregnant <24 months
Women were 21–40 years old (maximum 15% of total 
participants in the 35–40 age group) with a partner age 
21–50.
Women were excluded if using hormonal birth control or 
fertility drugs that contained hCG or LH, had a medical 
condition that presented a risk if they became pregnant or 
had been attempting to become pregnant >2 years.
RCT (consumer satisfaction 
questionnaire mailed after 
completing study)
Sample size: 305 women
Clearblue Easy 
Fertility Monitor







Couples attempting to become pregnant <12 months 
reporting concern over lack of success.
Women were 18–44 years old, in a mutually monogamous 
relationship with a male partner and English-literate. Women 
had never undergone infertility investigation or treatment, 
regular cycles (21–42 days), at least 3 months after stopping 
hormonal contraception, last pregnancy or breastfeeding, at 
least 13 cycles after a last Depo-Provera injection
Women were excluded if using hormonal medication or had 
liver or kidney disease, polycystic ovarian syndrome or any 
medical condition that would put the volunteer at risk if she 
were to become pregnant.
Prospective cohort study 
(acceptability assessments 
every cycle for four cycles)
Sample size: 61 couples
Clearplan Easy 
Fertility Monitor
Jones et al, 
201528 and
Tiplady et al, 
201324
UK (national) Women attempting to become pregnant <12 months
Women were 18–40 years old who had regular menstruation 
and wished to become pregnant.
Women were excluded if they had used hormonal 
contraception in the last 3 months, were currently 
undergoing fertility treatment or investigation, had previously 
been diagnosed as infertile, had a history of depression, 
anxiety or panic attacks or were dependent on either drugs 
or alcohol. Women who had previously used ovulation tests 




with all participants after 
completing study)
Sample size: 210 women 
(qualitative analysis reached 
saturation after coding 18 





LH, luteinising hormone; OPK, ovulation predictor kit; RCT, randomised controlled trial.
Most interviewees could not think of any disadvan-
tages.24 28 However, some women mentioned detri-
mental effects on their sexual life and relationship with 
their partner, saying that sex became less spontaneous, 
exciting and romantic and that there were increased 
expectations and pressure. Some also described 
emotional consequences after prolonged OPK usage, 
such as dependence, obsession, self-doubt, demotivation 
and difficult-to-resolve questions/uncertainties. Though 
some participants reported stress when using OPKs, 
some reported stress when attempting to become preg-
nant without OPKs; overall, many felt that using OPKs 
decreased stress. Finally, women who became pregnant 
while using OPKs seemed to remember less how the test 
affected their sex life, compared with women who did not 
become pregnant.
One study in the USA among 61 couples attempting 
pregnancy25 found that, at baseline, women, compared 
with their male partners, expressed greater preference 
for the monitor and believed it would be more informa-
tive about the women's reproductive processes (multi-
variate analysis of variance [ANOVA] F(10,93)=4.779, 
p<0.0001). Curiously, initial acceptability was higher 
among couples who eventually became pregnant (multi-
variate ANOVA F(4,79)=2.50, p<0.05). All participants 
liked the OPK, expected it to improve their chance of 
becoming pregnant and expected the OPK to increase 
their knowledge concerning their female bodies and 
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about the process of reproduction. Among those who did 
not become pregnant, product acceptability and expecta-
tions of becoming pregnant decreased across four cycles 
while using an OPK, while feelings of sadness/anger/loss 
and strain/blame in the relationship increased.
As part of a prospective cohort study in Scotland in the 
1990s,21 researchers administered an acceptability ques-
tionnaire to the 63 couples who had used home ovula-
tion testing to time donor insemination and received 40 
responses (63%). Of these, 73% thought the kits expen-
sive, 86% found the kits easy to use and 75% found the 
result easy to interpret. 81% expressed confidence in 
their use, but a third would have liked further assistance 
in using the kits. Only half would prefer home testing in 
future cycles. Even with the convenience of home testing, 
67% felt that undergoing treatment with donor insem-
ination significantly interfered with their working lives. 
A retrospective study published in 1991 among 26 infer-
tility patients in the USA found that timing intercourse 
via OPKs could lead to emotional distress.27 However, 
they also stated that other events related to losing a 
pregnancy (eg, ectopic pregnancy, miscarriage) or not 
becoming pregnant (eg, negative pregnancy test, menses 
onset, seeing a pregnant woman) were more emotionally 
difficult than using the OPKs.
Finally, as part of a recent feasibility study in the USA 
on a ‘Knowing your Body’ (family planning/fertility 
awareness) kit which included ovulation test strips, a 
survey was conducted among a convenience sample of 
low-income, racial/ethnic minority, urban, medically 
underserved women.26 Ninety-one per cent had used the 
OPKs included in the kit; of these, 77% were extremely 
or very confident that they could properly use the test 
strip to know when they were ovulating and, in addition, 
73% were comfortable using the OPK.
dIsCussIon
Fertility management when attempting a desired preg-
nancy is an important issue for women and couples 
globally. This review evaluated the benefits and risks of 
using OPKs as a self-care intervention to time conception 
compared with provider testing or no ovulation predic-
tion. Two RCTs measured time-to-pregnancy and found 
no difference in time-to-pregnancy between OPK and 
non-OPK users.23 24 Three RCTs found either no differ-
ence in clinical pregnancy rate22 or higher self-reported 
pregnancy rates23 24 among women using home-based 
OPKs. One observational study from the mid-1990s found 
reduced clinical pregnancy rates among women who 
used OPKs to time a donor insemination.21 One study 
reporting several indicators for stress/anxiety found no 
difference in stress as measured by questionnaires or 
biochemical markers, though they did find one decrease 
in positive affect.24 No included studies reported compar-
ative data on live birth or other social harms/adverse 
events.
In terms of values and preferences, women who had 
used or heard of OPKs were usually highly satisfied: they 
found the kits easy to use and understand, convenient 
and accurate. Almost all women were confident in their 
ability to use the kit and in its ovulation predictive ability. 
Users appreciated knowing more about their menstrual 
cycle and timing to attempt pregnancy, which decreased 
stress, provided emotional support and enabled team-
work with their partner. However, especially in those 
who did not achieve pregnancy, an overdependence on 
OPKs could decrease spontaneity and foster obsession 
and doubt. Most participants stated that they would use 
OPKs again in the future. The one study with less confi-
dence about OPKs took place in the 1990s; the value of 
these participants' opinions on ease of use and ease of 
interpretation is limited, given changes in the OPKs now 
available. Though some reported stress and increasing 
dissatisfaction from prolonged use of OPKs, especially 
among couples who did not achieve pregnancy, OPK 
usage caused less emotional distress than other preg-
nancy (loss)-related events.
strengths and limitations
This systematic review included multiple study designs: 
both randomised trials and observational studies. For 
comprehensiveness, we searched multiple databases and 
conducted secondary and hand searching, and we did not 
exclude studies based on language or location or publica-
tion date. Screening and data extraction were conducted 
in duplicate and resolved via consensus. Where possible, 
we used meta-analysis when presenting quantitative find-
ings. Another strength is our combination of quantitative 
evidence on benefits and harms with more qualitative 
values and preferences.
However, this review is limited in the depth and quality 
of its evidence base. Overall, the quality of evidence 
was low to very low, as blinding was impossible (poten-
tially leading to detection and reporting biases). One 
RCT with 1453 participants reporting pregnancies, live 
birth and stress/anxiety29 could not be analysed because 
its results have not yet been presented by intervention 
group; its findings could potentially impact the results 
of this review. Three of the included studies were very 
small, with 210 or fewer total participants each.21 22 24 
Only two studies reported clinical pregnancy rates, both 
conducted in the 1990s.21 22 It is unclear if the current 
OPKs are more accurate and effective than those used 
decades ago. Stress and anxiety were only reported in 
one study from a high-income country,24 and no other 
comparative reports of social harms/adverse events were 
found. Further research is needed to assess the evidence 
on these outcomes in both high-resource and lower-re-
source settings, and within different sociocultural envi-
ronments which may place a higher value on pregnancy 
and childbearing.
Two recent RCTs presented pregnancy rates and time-
to-pregnancy based on positive pregnancy tests from the 
first two menstrual cycles.23 24 Self-reported pregnancy 
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rates early in pregnancy unconfirmed by ultrasound have 
somewhat limited clinical relevance, given the risk for 
early miscarriage, but these results still support the poten-
tial for OPKs to improve timed intercourse for achieving 
pregnancy. Short follow-up across studies (2–6 cycles) 
limited assessment of differences between the interven-
tion and control groups, especially since pregnancy is a 
relatively rare event (particularly in couples defined as 
infertile—12 months of attempting—or when infertility 
may be due to a functional disability). This follow-up 
length also precluded assessment of clinically important 
outcomes such as live birth, but maintenance of a preg-
nancy resulting in a live birth can be due to many factors 
unrelated to an ability to become pregnant. In addition, 
couples' expectations and perceived stress could be miti-
gated if they realised it commonly takes more than 2–6 
cycles to become pregnant; some studies claim an 85% 
chance of becoming pregnant within 12 cycles.30 31
All studies used urinary fertility monitoring, and most 
used the same commercially available OPK (Clearblue). 
No studies were found on the effectiveness of other 
modes or types of OPK. Participant populations varied 
by study, which may affect pooled results: two studies 
focused on couples undergoing fertility treatment or 
investigation,21 22 while the others recruited women and 
couples attempting pregnancy from the general popula-
tion.23 24 The control groups in each study also differed: 
some received general recommendations on timing 
condom-less intercourse,22–24 one allowed participants to 
use other pregnancy aids,23 one requested participants 
to abstain from other ovulation-timing methods24 and 
one collected urine specimens for lab testing.21 Addi-
tional high-powered RCTs that provide all participants 
with menstrual cycle and reproduction-timing educa-
tion, provide information about realistic expectations 
on chance of pregnancy per cycle attempts and also give 
participants a fertility assessment prior to study inclusion 
in order to ensure potential capacity to become preg-
nant and carry a child to term (fecundability) through 
appropriately timed condom-less intercourse, would 
strengthen the evidence base. If vaginal insemination is 
used with donor semen, these participant data need to 
be appropriately disaggregated. If women are found to 
have a lower ovarian reserve or if men are found with 
lower quality semen parameters, these participant data 
also need to be appropriated disaggregated. All included 
studies took place in high-income countries; thus, addi-
tional research evidence is needed from participants 
from lower-resource settings.
It is challenging to determine the effectiveness of 
OPKs, given the paucity of evidence for benefits and 
harms. Generally, our results on effectiveness agree 
with the 2015 review by Manders et al,8 which found that 
urinary fertility monitoring to time intercourse could 
lead to higher pregnancy rates with no increase in stress.
Given that over 186 million couples worldwide suffer 
from infertility and childlessness2 and Global Burden 
of Disease and Disability data indicate global levels of 
primary and secondary infertility have hardly changed 
between 1990 and 2010,1 it is imperative to find innova-
tive solutions to support couples with safe, affordable, 
acceptable and accessible options to ensure that all 
women, including infertile women and couples, are able 
to plan for their fertility goals and achieve pregnancy 
safely. Findings presented in this review have been used 
to inform the development of WHO recommendations 
for self-care interventions for sexual and reproductive 
health and rights relating to use of home-based OPKs. 
The benefits and harms, and values and preferences, 
of this intervention have been considered along with 
resource use, human rights and feasibility issues to inform 
the recommendation. We hope that additional research 
regarding the outcomes important to decision-makers 
will be conducted to provide the evidence required to fill 
the gaps identified in the current literature.
ConClusIon
Ensuring that policies and programmes support the 
desire of women’s and couples’ sexual and reproduc-
tive desires and rights requires innovative approaches. 
Home-based use of OPKs has the potential to empower 
couples and women who are attempting to become preg-
nant. As an additional resource for fertility management, 
OPKs may increase the likelihood of becoming pregnant 
and generally have not been found to cause additional 
stress/anxiety especially among those who do become 
pregnant. OPKs have been found highly acceptable by 
end-users. They also improve end-users' fertility aware-
ness and knowledge, enabling women to know their 
bodies better. However, more research is needed to assess 
time-to-pregnancy, pregnancy rates, stress/anxiety, social 
harms/adverse events and values and preferences using 
a diverse set of OPKs (beyond Clearblue), especially in 
low-resource settings (eg, low-income and middle-in-
come countries), and with longer follow-up time periods. 
Further research for understanding the complex influ-
ence of social constructs, treatment and technology 
availability and service integration on the realisation of 
desired pregnancies among vulnerable populations will 
be particularly important.
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